
Currently out of the existing stock ratings of Matthew Luchini, 61 are a HOLD (39.35%), 94 are a BUY (60.65%).
Analyst Matthew Luchini, has had 46.43% of price targets met with an average potential upside of 22.21%, reached in 310 days on average. Previously, Matthew Luchini worked at BMO.
Matthew Luchini has documented 303 price targets and ratings displayed on 31 stocks. The coverage was on Healthcare, Industrials, Energy, Technology sectors.
Most recent stock forecast was given on REPL, Replimune Group at 18-Mar-2022.
Analyst best performing recommendations are on ONCE (SPARK THERAPEUTICS).
The best stock recommendation documented was for ONCE (SPARK THERAPEUTICS) on 8/6/2018. The price target of $60 was fulfilled within 1 day with a profit of $17.61 (22.69%), with a performance score of 226.9.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 11-Feb-2015
4 years 22 days ago
(25-Oct-2022)
2/13 (15.38%)
$13.99 (348.88%)
660
Hold Since 25-Oct-2022
$0.4
4 years 22 days ago
(25-Oct-2022)
1/1 (100%)
$0.01 (2.56%)
2
Hold Since 24-Oct-2022
$0.34
4 years 23 days ago
(24-Oct-2022)
0/5 (0%)
$-0.05 (-12.82%)
Buy Since 09-Feb-2017
$9
4 years 23 days ago
(24-Oct-2022)
0/3 (0%)
$7.17 (391.80%)
Buy Since 11-Nov-2020
$11
4 years 1 months 18 days ago
(29-Sep-2022)
0/2 (0%)
$6.72 (157.01%)